Open AccessThe position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society
Author(s) -
З. Р. Айсанов,
S. N. Avdeev,
Andrey Belevskiy,
А. А. Визель,
A. V. Еmelyanov,
Г. Л. Игнатова,
О М Курбачева,
И. В. Лещенко,
Natalia Nenasheva,
С. И. Овчаренко,
А. И. Синопальников,
Olga Titova
Publication year - 2021
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2021-31-1-66-74
Subject(s) - indacaterol , mometasone furoate , inhaler , asthma , medicine , inhalation , corticosteroid , anesthesia , bronchodilator
Achieving the control of bronchial asthma (BA) in real clinical practice remains an unresolved problem, despite the expansion of therapeutic options in this area. Guidelines about when and for whom should a particular treatment be used continue to develop. Increasing of inhaled corticosteroid dose (ICS) in combination with a long-acting β 2 -agonist (LABA) does not always lead to the desired result, although a combined LABA-ICS inhaler could improve the course of asthma and increase adherence. The addition of tiotropium bromide to LABA-ICS requires the use of two inhalers. The targeted biological therapy is associated with the complexity of phenotyping and is possible only in specialized medical centers. Mometasone furoate, indacaterol acetate, and glycopyrronium bromide in fixed doses were combined in Breezhaler® inhaler for asthma maintenance therapy once per day. This way of treatment helps to realize full potential of maintenance inhalation therapy of bronchial asthma and to simplify the achievement of control over the disease in routine clinical practice.